Revolution Medicines, Inc.
RVMD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001628171
In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 16 sales; 693 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesRVMDW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $76.9M in total
- 16
- 13F holdersQ2 2026, +182 vs. previous quarter
- 693
- 13F valueReported value at the end of Q2 2026
- $40.1B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding RVMD, Q2 2026
1 superinvestor reports holding Revolution Medicines, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
1.7%
Revolution Medicines, Inc.'s share of the portfolio
- Shares
- 399,587
- Value
- $74.8M
Latest insider trades
Open-market purchases and sales by Revolution Medicines, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)6:00 PM ET | Sep 22 | 2 days | Anderson Elizabeth MDirector | SSale | −10.1K | $193.04 | −$1.96M | −70.1%4.33K after | 5 lots10b5-1 |
| Sep 22, 2026 (view filing)6:00 PM ET | Sep 18 | 4 days | Mancini AnthonySee Remarks | SSale | −1.76K | $196.94 | −$347.4K | −4.2%40.4K after | 10b5-1 |
| Sep 18, 2026 (view filing)6:06 PM ET | Sep 16 | 2 days | Sandler Alan B.Chief Development Officer | SSale | −341 | $199.24 | −$67.9K | −0.6%52.9K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:05 PM ET | Sep 16 | 2 days | Mancini AnthonySee Remarks | SSale | −1.77K | $199.24 | −$353.4K | −4.0%42.1K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:04 PM ET | Sep 16 | 2 days | Kelsey Stephen MichaelSee Remarks | SSale | −5.57K | $199.24 | −$1.11M | −1.9%286.3K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:03 PM ET | Sep 16 | 2 days | Horn Margaret AChief Operating Officer | SSale | −4.97K | $199.24 | −$989.6K | −3.2%149.7K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:02 PM ET | Sep 16 | 2 days | Goldsmith Mark ASee Remarks | SSale | −14.0K | $199.24 | −$2.79M | −5.2%253.3K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:01 PM ET | Sep 16 | 2 days | Cislini JeffSVP & General Counsel | SSale | −3.37K | $199.24 | −$670.6K | −6.0%52.5K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:00 PM ET | Sep 16 | 2 days | Anders JackChief Financial Officer | SSale | −4.05K | $199.24 | −$807.5K | −3.3%119.2K after | 2 lots10b5-1 |
| Sep 15, 2026 (view filing)6:00 PM ET | Sep 11 | 4 days | Kelsey Stephen MichaelSee Remarks | SSale | −92.5K | $202.36 | −$18.7M | −24.1%291.9K after | 8 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Revolution Medicines, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,695,790 | $2.56B | 0.04% | +2,483,084+22.1% | Added |
| Farallon Capital Management, L.L.C. | 13,550,796 | $2.54B | 14.86% | −54,000−0.4% | Reduced |
| FMR LLC | 12,200,422 | $2.28B | 0.10% | +3,736,108+44.1% | Added |
| Baker Bros. Advisors LP | 11,443,357 | $2.14B | 10.74% | +1,888,000+19.8% | Added |
| Darwin Global Management, Ltd. | 10,629,822 | $2.05B | 54.45% | +8,418,804+380.8% | Added |
| Jupiter Topco LLC | 10,736,145 | $2.01B | 0.82% | +10,736,145 | New |
| Vanguard Capital Management LLC | 9,088,661 | $1.70B | 0.04% | +726,377+8.7% | Added |
| Vanguard Portfolio Management LLC | 8,294,855 | $1.55B | 0.07% | +792,232+10.6% | Added |
| Nextech Invest, Ltd. | 7,601,087 | $1.42B | 67.55% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 6,361,323 | $1.19B | 22.31% | −294,380−4.4% | Reduced |